World Leader in Cross-Caval
Approach for TR Treatment

Innoventric Secures $28.5M in Series B Funding!

Innoventric is thrilled to announce the enrollment of its first Trillium™ EFS patient.
The case was performed at TriStar Centennial Medical Center, in Nashville, TN.
We congratulate Dr. Samuel Horr, Dr. Andrew Goodman, and the exceptional Tristar Centennial Medical Center team. Thank you for your outstanding commitment, professionalism, and teamwork!
The implantation procedure for the experimental Trillium™ system took only 5 minutes (device implantation time), with immediate and significant hemodynamic improvements, such as V-wave CVP reduction of 12 mmHg and a cardiac output increase from 6 L/min to 9.6 L/min.

Join Philipp Lurz and Rodrigo Estevez Loureiro as they discuss with Marta Sitges a groundbreaking treatment for tricuspid regurgitation involving the implantation of heterotopic prostheses.

Innoventric is excited to share the successful treatment of our first two North American patients!
The credit goes to the incredible St. Michael's Hospital team in Toronto, led by Dr. Neil Fam, Dr. Sami Alnasser, and Dr. Geraldine Ong. Thank you for the great professionalism and collaboration!
Both patients had been turned down by many other interventional treatments, including TEER, TTVR, and bi-caval valve replacement. However, with our Unica™, heterotopic cross-caval TR solution, they were successfully treated.
Both procedures were short and straightforward, taking only 5 minutes for device implantation and 10 minutes for skin-to-skin time.
Both procedures did not require general anesthesia and were performed under conscious sedation. Also, echo guidance is not required with Innoventric’s cross-caval technologies, so TEE was not performed.
The post-procedural effect was marked- a significant cardiac output increase and venous pressure reduction.
Both patients had an uneventful procedure and recovery and were discharged from the hospital the next day.

Innoventric is happy to announce the FDA approval of its IDE application for the Trillium™ early feasibility study (EFS)!
The EFS will include up to 15 patients at multiple clinical sites, and patient enrollment is expected to begin in the first quarter of 2024.

Innoventric is happy to announce that we have completed the Trillium™ FIH study patient enrollment. The study was conducted in Israel, Germany, Belgium, and Spain and included 20 patients. The longest patient follow-up is 2.5 years, with excellent results.

Innoventric is happy to announce the first implantation of its Unica™ device. The credit goes to Dr. Rodrigo Estévez Loureiro, Marta Tavares da Silva, Dr. Jose Antonio Baz, Manuel Barreiro Pérez, Jose Antonio Parada, Alavaro Rodriguez, and their team at Hospital Alvaro Cunqueiro (Vigo). Thank you for a great case!

Israeli Medical Device Startup, Innoventric Ltd., Wins the Prestigious Horizon Europe Grant.
Innoventric was among 4,000+ applicants for the first Horizon Europe submission and was acknowledged among the top 65 (1.5%) technology companies after a very long and competitive process. The company was granted with the maximal grant support of €2.5M.
“We are extremely proud of our Horizon Europe achievement and want to thank the European Commission for acknowledging our company and technology. This prestigious prize provides us with the highest seal of excellence granted by the European Union to a technological start-up” [Amir Danino, Founder and CEO]

Innoventric has raised $14M funding for its Trillium™ technology to treat tricuspid valve regurgitation.
The Series A financing, which is led by a US-based investor, includes a €2.5m grant from Horizon Europe, which is 6-year program launched by the European Union this year to support groundbreaking technologies.
A new European investor and all previous round participants also took part in the funding round of the company, which was founded in 2017.

Innoventric’s technology is acknowledged by the Israeli Innovation Authority (IIA)